HONG KONG: ADC Therapeutics SA, a Swiss biotechnology company whose backers include UK drugmaker AstraZeneca Plc, is in the early stages of exploring options including an initial public offering (IPO) amid growing interest in innovative cancer treatments, according to people familiar with the matter.
ADC is working with advisers at Morgan Stanley on a preliminary review, the people said, asking not to be identified because the deliberations are private.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
